• Corpus ID: 85878511

Perspectives in Renin-Angiotensin-Aldosterone System Blockade: What's New?

  title={Perspectives in Renin-Angiotensin-Aldosterone System Blockade: What's New?},
  author={Pitchai Balakumar and Nidhi Sharma and Sonam Kathuria and Lalita Babbar and Nanjaian Mahadevan},
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the regulation of cardiovascular-renal function. However, its overactivation results in cardiovascular and renal abnormalities. Thus, drugs depressing the overactivity of RAAS are of potential therapeutic value in the management of cardiovascular and renal complications. The RAAS overactivation could be effectively inhibited by various agents at its different stages by means of inhibiting angiotensin-II (Ang-II) formation from… 
The renin–angiotensin system (RAS) has an important role in the control of blood pressure, hypertension, diabetes, and in the regulation of salt and volume homeostasis of organisms as well as in the
Upregulation of Renin Angiotensin Aldosterone System (RAAS) by Methylglyoxal: Role in Hypertension
This review focuses on the literature review of hypertension and its role in diabetes, as well as some of the mechanisms behind its prevalence and treatment.


ACE2 of the heart: From angiotensin I to angiotensin (1-7).
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat.
Both renin inhibition and blockade of the AT(1)R significantly attenuated cardiac functional and structural alterations, although irbesartan treatment resulted in greater reductions of both blood pressure and markers of oxidative stress.
Optimal Antagonism of the Renin-Angiotensin-Aldosterone System
Combined therapy with several RAAS inhibitors is not recommended for all patients along the cardiorenovascular continuum, but patients with CHF with incomplete neuroendocrine blockade, as indicated, for example, by repetitive cardiac decompensation or refractory symptoms, might benefit from dual therapy as long as safety issues are well controlled.
The (pro)renin receptor: therapeutic consequences
Unexpectedly, this receptor also induced angiotensin-independent effects, suggesting that renin and/or prorenin may act as agonists for this receptor, and this could lead to the development of (pro)renin receptor blockers (i.e., drugs that not only prevent tissue angiotENSin generation but also inhibit renin- or Prorenin-induced effects).
Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker
In conclusion, triple blockade of the RAAS was effective for the treatment of proteinuria in patients with non-diabetic nephropathy whose increased urinary protein had not responded sufficiently to a dual blockade.
Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension
Early data suggest a role for aliskiren in preventing end-organ damage but, considering the ONTARGET results with an ACE-I-ARB combination, outcome studies are needed before the use of aliskirens can be recommended in combination with other RAS inhibitors.
The frail renin-angiotensin system.
  • P. Abadir
  • Biology, Medicine
    Clinics in geriatric medicine
  • 2011
The Role of Aldosterone Blockers in the Management of Chronic Heart Failure
The pathophysiology of CHF, the beneficial role of aldosterone antagonists in this disease process, and potential adverse consequences of these agents are reviewed.
Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage
Aldosterone plays a key role in the pathogenesis of Ang II–induced organ damage and the present results show that aldosterone produced in the adrenals is the main source of cardiac ald testosterone.
Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.
It is concluded that renin upregulates MC TGF-beta1 through a receptor-mediated mechanism, independent of Ang II generation or action, and may contribute to renal fibrotic disease, particularly when therapeutic Ang II blockade elevates plasma renin.